1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2022, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 17, 18, 3, 55, 24 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.
Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Chronic Kidney Disease (Chronic Renal Failure) - Overview
- Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
- Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles
- Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
- Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
- Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
- Featured News & Press Releases
- Jul 11, 2022: Algernon Pharmaceuticals provides update on its planned phase 1 repirinast chronic kidney disease study
- Jun 30, 2022: Kerendia (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes
- Jun 28, 2022: Bayer’s KERENDIA (finerenone) receives new recommendations from American Diabetes Association for improving cardiovascular outcomes and managing patients with chronic kidney disease associated with type 2 diabetes
- Jun 23, 2022: ProKidney corroborates the mechanism of action of REACT with cell marker analysis in patients with diabetic chronic kidney disease
- Jun 15, 2022: ProKidney announces manufacturing efficiency initiatives and supply chain streamlining expected to reduce REACT Manufacturing Costs
- Jun 07, 2022: Observed safety profile supports bilateral dosing of ProKidney’s REACT - 007 update
- Jun 05, 2022: Bayer to present new Kerendia (finerenone) data from comprehensive clinical trial program across a broad range of patients with chronic kidney disease and type 2 diabetes
- Jun 01, 2022: CinCor Pharma doses first patient in phase 2 FigHTN-CKD trial evaluating the selective aldosterone synthase inhibitor baxdrostat (CIN-107) in patients with uncontrolled hypertension and chronic kidney disease
- May 23, 2022: New data support renal and cardiovascular benefits of Kerendia (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes
- May 17, 2022: Bayer to present new Kerendia (finerenone) data from comprehensive clinical trial program in chronic kidney disease and type 2 diabetes
- May 03, 2022: ProKidney highlights key registrational program elements supporting advancement of REACT
- Apr 26, 2022: Algernon Pharmaceuticals announces lead chronic kidney disease drug repirinast reduced fibrosis by 56% in a preclinical NASH study
- Apr 13, 2022: Renibus Therapeutics strengthens IP position with additional US patent
- Apr 12, 2022: ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT
- Apr 12, 2022: Caladrius Biosciences treats first patient in the phase 1b trial of CLBS201 for the treatment of diabetic kidney disease
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AdAlta Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algernon Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algomedix Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Anagenics Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angiotensin Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aria Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aronora Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Asahi Kasei Pharma Corp, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ashvattha Therapeutics LLC, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BerGenBio ASA, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim International GmbH, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Caladrius Biosciences Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ceptur Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chinook Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CinCor Pharma Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cinkate Corp, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Coegin Pharma AS, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Daiichi Sankyo Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DJS Antibodies Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eagle Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eli Lilly and Co, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ennovabio, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evopoint Bioscience Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec SE, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Future Medicine Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by G&P Bioscience Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by G3 Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gila Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Goldilocks Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gubra ApS, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Helixmith Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Hybridize Pharma BV, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Icagen Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by iCELL Biotechnology Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by INVENT Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ionis Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Jnana Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP Biosciences Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Kibow Biotech Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KidneyCure Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Liminal BioSciences Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lung Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Maze Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by MD Healthcare Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by MedBiome Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Meridigen Biotech Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by NovMetaPharma Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novo Nordisk AS, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Oisin Biotechnologies, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Oneness Biotech Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Orgenesis Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OrthoTrophix Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Pharmaxis Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Pharmicell Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Poxel SA, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProKidney LLC, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Purespring Therapeutics Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by RAGE Biotech Pty Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Rege Nephro Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reliance Life Sciences Pvt Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Renibus Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sarfez Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Scohia Pharma Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Senda Biosciences Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Senolytic Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sentien Biotechnologies Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Suzhou Regend Therapeutics Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by TagCyx Biotechnologies, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicocell Biomed Co Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicycive Therapeutics Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicyte AG, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vertex Pharmaceuticals Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vidasym Inc, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vivazome Therapeutics Pty Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vivoryon Therapeutics NV, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Zydus Lifesciences Ltd, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, 2022
- Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, 2022 (Contd..2)
- Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AdAlta Ltd
- Algernon Pharmaceuticals Inc
- Algomedix Inc
- Allena Pharmaceuticals Inc
- Anagenics Ltd
- Angion Biomedica Corp
- Angiotensin Therapeutics Inc
- Arch Biopartners Inc
- Aria Pharmaceuticals Inc
- Aronora Inc
- Asahi Kasei Pharma Corp
- Ashvattha Therapeutics LLC
- AstraZeneca Plc
- Bayer AG
- BerGenBio ASA
- BioAegis Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Boryung Pharmaceutical Co Ltd
- Caladrius Biosciences Inc
- Ceptur Therapeutics Inc
- Chinook Therapeutics Inc
- Chong Kun Dang Pharmaceutical Corp
- CinCor Pharma Inc
- Cinkate Corp
- Coegin Pharma AS
- Daiichi Sankyo Co Ltd
- DiaMedica Therapeutics Inc
- Dimerix Ltd
- Dizal (Jiangsu) Pharmaceutical Co Ltd
- DJS Antibodies Ltd
- DURECT Corp
- Eagle Pharmaceuticals Inc
- Eli Lilly and Co
- Ennovabio
- Evopoint Bioscience Co Ltd
- Evotec SE
- Future Medicine Co Ltd
- G&P Bioscience Co Ltd
- G3 Pharmaceuticals Inc
- Gila Therapeutics Inc
- GNI Group Ltd
- Goldilocks Therapeutics Inc
- Gubra ApS
- Haisco Pharmaceutical Group Co Ltd
- Hangzhou Metai Pharmaceutical Technology Co Ltd
- Helixmith Co Ltd
- Hybridize Pharma BV
- Icagen Inc
- iCELL Biotechnology Co Ltd
- INVENT Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Jnana Therapeutics Inc
- KBP Biosciences Co Ltd
- Kibow Biotech Inc
- KidneyCure Ltd
- Klotho Therapeutics Inc
- Liminal BioSciences Inc
- Lung Therapeutics Inc
- Maze Therapeutics Inc
- MD Healthcare Inc
- MedBiome Inc
- Meridigen Biotech Co Ltd
- Novartis AG
- NovMetaPharma Co Ltd
- Novo Nordisk AS
- Oisin Biotechnologies
- Oneness Biotech Co Ltd
- OPKO Health Inc
- Opsidio LLC
- Orgenesis Inc
- OrthoTrophix Inc
- Pharmaxis Ltd
- Pharmicell Co Ltd
- Poxel SA
- ProKidney LLC
- Purespring Therapeutics Ltd
- RAGE Biotech Pty Ltd
- Reata Pharmaceuticals Inc
- Rege Nephro Co Ltd
- Reliance Life Sciences Pvt Ltd
- Renibus Therapeutics Inc
- Resverlogix Corp
- Sarfez Pharmaceuticals Inc
- Scohia Pharma Inc
- Senda Biosciences Inc
- Senolytic Therapeutics Inc
- Sentien Biotechnologies Inc
- Shanghai Pharmaceutical Group Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Suzhou Regend Therapeutics Co Ltd
- TagCyx Biotechnologies
- Unicocell Biomed Co Ltd
- Unicycive Therapeutics Inc
- Unicyte AG
- Vascular BioSciences
- Vertex Pharmaceuticals Inc
- VESSL Therapeutics Ltd
- Vidasym Inc
- Vivazome Therapeutics Pty Ltd
- Vivoryon Therapeutics NV
- Zydus Lifesciences Ltd
